SurModics Inc. (SRDX)

39.73
0.37 0.94
NASDAQ : Health Technology
Prev Close 39.36
Open 39.12
Day Low/High 38.70 / 40.01
52 Wk Low/High 38.06 / 61.72
Volume 64.74K
Avg Volume 89.90K
Exchange NASDAQ
Shares Outstanding 13.49M
Market Cap 527.23M
EPS 0.60
P/E Ratio 244.25
Div & Yield N.A. (N.A)

Latest News

Surmodics Breaks Above 200-Day Moving Average - Bullish For SRDX

Surmodics Breaks Above 200-Day Moving Average - Bullish For SRDX

In trading on Friday, shares of Surmodics Inc crossed above their 200 day moving average of $45.31, changing hands as high as $47.02 per share. Surmodics Inc shares are currently trading up about 7% on the day.

Surmodics To Webcast Fourth Quarter Fiscal 2019 Earnings Conference Call On October 31

Surmodics To Webcast Fourth Quarter Fiscal 2019 Earnings Conference Call On October 31

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its fourth quarter fiscal 2019 conference call on Thursday, October...

Surmodics Completes Enrollment In Pivotal TRANSCEND Clinical Trial

Surmodics Completes Enrollment In Pivotal TRANSCEND Clinical Trial

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced it has completed enrollment in TRANSCEND, its pivotal clinical trial for the SurVeil™ drug-coated balloon...

Notable Friday Option Activity: SRDX, IOVA, NGVC

Notable Friday Option Activity: SRDX, IOVA, NGVC

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Surmodics Inc , where a total of 671 contracts have traded so far, representing approximately 67,100 underlying shares. That amounts to about 71.3% of SRDX's average daily trading volume over the past month of 94,080 shares.

Surmodics Reports Third Quarter Fiscal 2019 Results And Raises Fiscal 2019 Revenue And EPS Guidance

Surmodics Reports Third Quarter Fiscal 2019 Results And Raises Fiscal 2019 Revenue And EPS Guidance

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2019 third quarter ended June 30, 2019, and updated its financial outlook for...

Surmodics To Webcast Third Quarter Fiscal 2019 Earnings Conference Call On July 31

Surmodics To Webcast Third Quarter Fiscal 2019 Earnings Conference Call On July 31

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its third quarter fiscal 2019 conference call on Wednesday, July 31,...

Notable Monday Option Activity: SRDX, ECOL, OMER

Notable Monday Option Activity: SRDX, ECOL, OMER

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Surmodics Inc , where a total volume of 577 contracts has been traded thus far today, a contract volume which is representative of approximately 57,700 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 47.1% of SRDX's average daily trading volume over the past month, of 122,560 shares.

Surmodics To Present At Jefferies Healthcare Conference

Surmodics To Present At Jefferies Healthcare Conference

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Tim Arens, vice president of finance and...

Surmodics Reports Second Quarter Fiscal 2019 Results

Surmodics Reports Second Quarter Fiscal 2019 Results

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2019 second quarter ended March 31, 2019, and updated its financial outlook for...

Surmodics To Webcast Second Quarter Fiscal 2019 Earnings Conference Call On May 1

Surmodics To Webcast Second Quarter Fiscal 2019 Earnings Conference Call On May 1

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its second quarter fiscal 2019 conference call on Wednesday, May 1,...

Surmodics Sublime™ Guide Sheath Receives FDA 510(k) Approval

Surmodics Sublime™ Guide Sheath Receives FDA 510(k) Approval

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced it has received U.

Surmodics Provides Update Regarding TRANSCEND Clinical Trial

Surmodics Provides Update Regarding TRANSCEND Clinical Trial

Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, has resumed patient enrollment into its TRANSCEND clinical trial and is nearly 75 percent of the way to its goal of...

Surmodics Enters Oversold Territory (SRDX)

Surmodics Enters Oversold Territory (SRDX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Surmodics To Present At Needham Healthcare Conference

Surmodics To Present At Needham Healthcare Conference

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Tim Arens, vice president of finance and...

Surmodics Breaks Above 200-Day Moving Average - Bullish For SRDX

Surmodics Breaks Above 200-Day Moving Average - Bullish For SRDX

In trading on Thursday, shares of Surmodics Inc crossed above their 200 day moving average of $59.47, changing hands as high as $61.08 per share. Surmodics Inc shares are currently trading down about 3.1% on the day.

Surmodics Announces Appointment Of Timothy J. Arens As Chief Financial Officer

Surmodics Announces Appointment Of Timothy J. Arens As Chief Financial Officer

Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced the appointment of Timothy J.

Surmodics To Host Virtual Annual Meeting Of Shareholders

Surmodics To Host Virtual Annual Meeting Of Shareholders

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, will hold its Annual Meeting of Shareholders on Wednesday, February 13, at 4 p.

Surmodics (SRDX) Shares Cross Above 200 DMA

Surmodics (SRDX) Shares Cross Above 200 DMA

In trading on Thursday, shares of Surmodics Inc crossed above their 200 day moving average of $58.34, changing hands as high as $60.66 per share. Surmodics Inc shares are currently trading up about 13.4% on the day.

Surmodics Reports First Quarter Fiscal 2019 Results

Surmodics Reports First Quarter Fiscal 2019 Results

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2019 first quarter ended December 31, 2018 and updated its financial outlook for...

Surmodics To Webcast First Quarter Fiscal 2019 Earnings Conference Call On January 30

Surmodics To Webcast First Quarter Fiscal 2019 Earnings Conference Call On January 30

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its first quarter fiscal 2019 conference call on Wednesday, January...

Surmodics Reports Fourth Quarter Fiscal 2018 Results And Issues Fiscal 2019 Guidance

Surmodics Reports Fourth Quarter Fiscal 2018 Results And Issues Fiscal 2019 Guidance

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2018 fourth quarter ended September 30, 2018, and provided its financial outlook...

12-Month Data From Surmodics SurVeil® Drug-Coated Balloon Early Feasibility Study Presented At VIVA 2018

12-Month Data From Surmodics SurVeil® Drug-Coated Balloon Early Feasibility Study Presented At VIVA 2018

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced that data from the PREVEIL early feasibility study (EFS) of the company's SurVeil ® drug-coated balloon (DCB) was shared in a...

Surmodics Names Teri Sides As Chief Marketing Officer

Surmodics Names Teri Sides As Chief Marketing Officer

Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today Teri Sides has joined Surmodics as Senior Vice President and Chief Marketing Officer, effective November...

Surmodics To Webcast Fourth Quarter Fiscal 2018 Earnings Conference Call On November 9

Surmodics To Webcast Fourth Quarter Fiscal 2018 Earnings Conference Call On November 9

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its fourth quarter fiscal 2018 conference call on Friday, November 9,...

Surmodics Enters Oversold Territory (SRDX)

Surmodics Enters Oversold Territory (SRDX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Surmodics To Present At 7th Annual Intellisight Investor Conference

Surmodics To Present At 7th Annual Intellisight Investor Conference

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will participate in the 7 th Annual Intellisight Conference.

Surmodics Reports Third Quarter Fiscal 2018 Results

Surmodics Reports Third Quarter Fiscal 2018 Results

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2018 third quarter ended June 30, 2018, and updated its financial outlook for...

Surmodics IVD Launches Breakthrough MatrixGuard™ Diluent

Surmodics IVD Launches Breakthrough MatrixGuard™ Diluent

Surmodics, Inc. (NASDAQ: SRDX), the global leader in chemical components for in vitro diagnostic (IVD) tests and microarrays, has announced the launch and immediate availability of MatrixGuard™ Diluent.

TheStreet Quant Rating: C (Hold)